Results 171 to 180 of about 7,348 (201)
Some of the next articles are maybe not open access.
Mesalamine-induced eosinophilic pleural effusion
BMJ Case Reports, 2020A 45-year-old woman with a medical history of ulcerative colitis (UC) presented with difficulty in breathing. The patient was diagnosed with UC a month prior to presentation and was started on mesalamine suppository. Chest x-ray (CXR) on presentation showed bilateral pleural effusion, which was confirmed on CT angiogram of the chest.
Abdullah Al-abcha +3 more
openaire +2 more sources
Rowasa Suspension Enema (Mesalamine, USP)
Gastroenterology Nursing, 1989Rowasa (mesalamine) rectal suspension enema, a new product by Reid-Rowell, represents a major breakthrough in the treatment of distal ulcerative colitis. It provides patients with an alternative therapy to the current oral and enema preparations. This treatment reduces the incidence of unwanted side effects and toxicity associated with oral therapy.
CECELIA A. CIARLEGLIO, Melanie L. Swartz
openaire +2 more sources
MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations
Digestive and Liver DiseaseMedical therapy is the cornerstone of ulcerative colitis (UC) management and aims to induce and maintain remission. In case of mild-to-moderate UC, mesalamine (5-ASA) is the first-line option. 5-ASA requires local release at the level of the inflamed mucosa to exert its therapeutic action.
Ferdinando, D'Amico +3 more
openaire +2 more sources
Mesalamine Foam EnemaVersusMesalamine Liquid Enema in Active Left-Sided Ulcerative Colitis
The American Journal of Gastroenterology, 2008To determine in a noninferiority study whether mesalamine foam is as effective as mesalamine liquid enema for inducing clinical remission in patients with active left-sided ulcerative colitis (UC).In a multicenter investigator-blind trial, 375 patients with mild-to-moderate UC were randomized to receive mesalamine foam 1 g/80 mL/day or mesalamine ...
Cortot, Antoine +15 more
openaire +3 more sources
Connecticut medicine, 2010
Lung toxicity associated with 5-aminosalicylate (5-ASA) agents is very rare. We report the case of a 48-year-old man with ulcerative colitis who developed progressive shortness of breath while taking oral mesalamine. Chest imaging revealed a ground glass appearance in patchy areas distributed throughout the lung. He had a restrictive ventilatory defect
Neha, Jain +2 more
openaire +1 more source
Lung toxicity associated with 5-aminosalicylate (5-ASA) agents is very rare. We report the case of a 48-year-old man with ulcerative colitis who developed progressive shortness of breath while taking oral mesalamine. Chest imaging revealed a ground glass appearance in patchy areas distributed throughout the lung. He had a restrictive ventilatory defect
Neha, Jain +2 more
openaire +1 more source
Reviews in gastroenterological disorders, 2006
Most current drug delivery systems in the treatment of ulcerative colitis and Crohn's disease release the active drug at the least effective location for treatment. The pharmaceutical industry has been developing different delivery systems for Multi-Matrix System (MMX) mesalamine for the treatment of Crohn's disease and ulcerative colitis. The new oral
openaire +1 more source
Most current drug delivery systems in the treatment of ulcerative colitis and Crohn's disease release the active drug at the least effective location for treatment. The pharmaceutical industry has been developing different delivery systems for Multi-Matrix System (MMX) mesalamine for the treatment of Crohn's disease and ulcerative colitis. The new oral
openaire +1 more source
Headache During Mesalamine Therapy: A Case Report of Mesalamine-Induced Pseudotumor Cerebri
Journal of Pediatric Gastroenterology and Nutrition, 2001D, Rottembourg +5 more
openaire +2 more sources